Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy

Vaccine

Volumn 22, Issue 8, 2004, Pages 1024-1031

  Ferro, Valerie A ^a   Costa, Rosaria ^a   Carter, K Christine ^a   Harvey, Michael J A ^b   Waterston, Mary M ^b   Mullen, Alexander B ^a   Matschke, Christian ^c   Mann, Jamie F S ^a   Colston, Angela ^d   Stimson, William H ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ALTANA PHARMA AG   (Germany)

^d Triveritas Ltd   (United Kingdom)

Author keywords

Anti fertility; GnRH; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; CYSTEINYLHISTIDYLTRYPTOPHYLSERYLTYROSYLGLYCYLLEUCYLARGINYLPROLYGLYCINAMIDE; GONADORELIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; PEPTIDE; POLYGLACTIN; QUIL A; SURFACTANT; TETANUS TOXOID; TRIACETIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; ATROPHY; CASTRATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; FERTILITY; GONAD; IMMUNE RESPONSE; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT;

EID: 10744229318     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.08.043     Document Type: Article

References (28)

1. Ferro V. Current advances in anti-fertility vaccines for fertility control and non-contraceptive applications. Expert Rev Vaccines 2002;1:443-52.
2. Zeng X.Y., Turkstra J.A., Meloen R.H.et al. Active immunization against gonadotrophin-releasing hormone in Chinese male pigs: effects of dose on antibody titer, hormone levels and sexual development. Anim. Reprod. Sci. 70:2002;223-233.
3. Kiyma Z., Adams T.E., Hess B.W., Riley M.L., Murdoch W.J., Moss G.E. Gonadal function, sexual behavior, feedlot performance, and carcass traits of ram lambs actively immunized against GnRH. J. Anim. Sci. 78:2000;2237-2243.
4. Ferro V.A., Stimson W.H. Anti-gonadotropin releasing hormone vaccines and their potential use in the treatment of hormone responsive cancers. BioDrugs. 12:1999;1-12.
5. Thompson D.L. Immunization against GnRH in male species (comparative aspects). Anim. Reprod. Sci. 60-61:2000;459-469.
6. Ferro V.A., Stimson W.H. Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine. Vaccine. 16:1998;1095-1102.
7. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
8. Ferro V.A., Stimson W.H. Effects of adjuvant, dose and carrier pre-sensitisation on the immunisation efficacy of a GnRH analogue. Drug Des. Discov. 14:1996;179-195.
9. Williams D., Mullen A.B., Baillie A.J., Carter K.C. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J. Pharm. Pharmacol. 50:1998;1351-1356.
10. Tiong G.K., Gill H.S., Lofthouse S., Puri N.K. Comparison of conventional adjuvants and 'adjuvant-free' monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin. Vaccine. 11:1993;425-430.
11. Ferro V.A., O'Grady J.E., Notman J., Stimson W.H. An investigation into the immunogenicity of a GnRH analogue in male rats: a comparison of the toxicity of various adjuvants used in conjunction with GnRH-glycys. Vaccine. 14:1996;451-457.
12. Matschke C., Isele U., van Hoogevest P., Fahr A. Sustained-release injectables formed in situ and their potential use for veterinary products. J. Control Release. 85:2002;1-15.
13. Ferro V.A., Khan M.A., Earl E.R., Harvey M.J., Colston A., Stimson W.H. Part I. Influence of carrier protein conjugation site and terminal modification of a GnRH-I peptide sequence in the development of a highly specific anti-fertility vaccine. Am. J. Reprod. Immunol. 48:2003;361-371.
14. Ferro V.A., Harvey M.J., Colston A., Stimson W.H. Part II. Influence of dimerization of a modified GnRH-I peptide sequence on a male antifertility vaccine. Am. J. Reprod. Immunol. 48:2003;372-380.
15. Ferro V.A., Khan M.A., Latimer V.S., Brown D., Urbanski H.F., Stimson W.H. Immunoneutralisation of GnRH-I, without cross-reactivity to GnRH-II, in the development of a highly specific anti-fertility vaccine for clinical and veterinary use. J. Reprod. Immunol. 51:2001;109-129.
16. Turkstra J.A., Zengt X.Y., van Diepent J.T.et al. Performance of male pigs immunized against GnRH is related to the time of onset of biological response. J. Anim. Sci. 80:2002;2953-2959.
17. Raghuvanshi R.J., Mistra A., Talwar G.P., Levy R.J., Labhasetwar V. Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. J. Microencapsul. 18:2001;723-732.
18. Raghuvanshi R.S., Katare Y.K., Lalwani K., Ali M.M., Singh O., Panda A.K. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int. J. Pharm. 245:2002;109-121.
19. Lipford G.B., Wagner H., Heeg K. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. Vaccine. 12:1994;73-80.
20. Fernando G.J., Stewart T.J., Tindle R.W., Frazer I.H. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. Scand. J. Immunol. 47:1998;459-465.
21. Weissman D.N., Hubbs A.F., Huang S.H., Stanley C.F., Rojanasakul Y., Ma J.K. IgG subclass responses in experimental silicosis. J. Environ. Pathol. Toxicol. Oncol. 20(Suppl. 1):2001;67-74.
22. Kyd J.M., Cripps A.W. Modulation of antigen-specific T and B cell responses influence bacterial clearance of non-typeable Haemophilus influenzae from the lung in a rat model. Vaccine. 14:1996;1471-1478.
23. Jakel T., Khoprasert Y., Kliemt D., Mackenstedt U. Immunoglobulin subclass responses of wild brown rats to Sarcocystis singaporensis. Int. J. Parasitol. 31:2001;273-283.
24. Shirodkar S., Hutchinson R.L., Perry D.L., White J.L., Hem S.L. Aluminum compounds used as adjuvants in vaccines. Pharm. Res. 7:1990;1282-1288.
25. Connacher M, Alexander J, Brewer JM, Niosomes as immunological adjuvants. In: Uchegbu IF, editior. Synthetic surfactant vesicles. Singapore: International Publishers Distributors Ltd.; 2000. p. 185-205.
26. Brewer J.M., Tetley L., Richmond J., Liew F.Y., Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol. 161:1998;4000-4007.
27. Newman K.D., Samuel J., Kwon G. Ovalbumin peptide encapsulated in poly(D,L lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J. Control Release. 54:1998;49-59.
28. Ghosh S., Jackson D.C. Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. Int. Immunol. 11:1999;1103-1110.